Product Description
Trastuzumab anti-Her2 monoclonal antibody control is designed and formulated for easy of use in quantitative or qualitative biological assays.
| Download Documents | |
|---|---|
| Product Sheet | |
| SDS | COA (Lot S705.S7.0630F) |
Trastuzumab is a humanized IgG1κ monoclonal antibody that specifically binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2/ErbB2). Trastuzumab is the active antibody in Herceptin® and forms the antibody component of HER2-targeted antibody drug conjugates such as ado-trastuzumab emtansine and trastuzumab deruxtecan.
This research-use-only product is intended for use as a quantitative or qualitative control material in assays such as ELISA, flow cytometry, immunofluorescence (IF), immunohistochemistry (IHC), immunoprecipitation (IP), and Western blotting (WB). It may also be used to investigate trastuzumab-related biological mechanisms, subject to assay-specific validation.
The product is supplied as 100 μg of lyophilized material in a microcentrifuge tube and requires reconstitution before use. For bulk quantities and custom packaging requirements, please contact us for pricing and availability.
Key Features
- Lyophilized from a histidine-buffered solution at pH 5.5-6.0.
- Accurate protein amount determined by UV/HPLC.
- Ready for use following constitution with sterile water.
Applications
- ELISA, flow cytometry, IF, IHC, IP, and WB.
- Neutralization and other functional assays
- Antibody engineering or development
- Quantitative or qualitative assay controls
Antibody Information
- Molecular Weight: Approximately 148 kDa
- Target: HER2/ErbB2
- Immunogen: Cells overexpressing human HER2/ErbB2
- Species Reactivity: Human and cynomolgus monkey. No detectable cross-reactivity with mouse or rat ErbB2/neu
- Expression Host: Chinese hamster ovary (CHO) cells, stable recombinant cell line
- Class/Isotype: Human IgG1 Kappa (IgG1k)
- Antibody Type: Monoclonal
- Purification Method: Multistep chromatographic purification, including Protein A affinity chromatography
- Purity: ≥99% monomeric by SEC-HPLC
- Physical Appearance: Colorless to white lyophilized powder in a microcentrifuge tube
Characterization of Trastuzumab by HPLC
Lot Number: S705.S7.0630F
Figure 1. SEC-HPLC profile of Trastuzumab anti-Her2 mAb Control showing ≥99% monomeric purity with no detectable aggregates.
Note: SEC separates the biopolymers by apparent MW or size in aqueous solution and is a very useful tool for assessing the level of aggregation in a biopolymer.
Figure 2. HIC-HPLC profile of Trastuzumab anti-Her2 mAb Control demonstrating a high degree of antibody homogeneity.
Note: HIC separates biopolymers based on hydrophobicity and is a useful tool for assessing the degree of heterogeneity in a biopolymer.
Frequently Asked Questions:
If you can’t find the answer you’re looking for or need information on general topics, please visit the main Frequently Asked Questions (FAQs) section.
Other Details
The information in this document is subject to change without notice. CellMosaic® assumes no responsibility for any errors or omissions that may appear in this document. Under no circumstances shall CellMosaic be liable, whether in contract, tort, warranty, or under any statute or on other legal theory, for special, incidental, indirect, punitive, multiple, or consequential damages related to or arising from this document, including but not limited to the use of this product thereof.CellMosaic’s products, including but not limited to AqT®, NeIon™, oxLink™ and sxLink™ (collectively, the “Products”), are covered by, or are the subject of, one or more issued patents and pending patent applications, including without limitation: 9,688,663 B2; 8,907,079 B2; 9,511,150 B2; 9,907,854 B2; 9,346,833 B2; 9,518,067 B2; CN104066451B; CN107043339B; CA 2,841,313; EP 2734238 B1; AU2012284055; JP 6240599 B2; and corresponding foreign patents and patent applications. The purchase of the Product conveys solely a limited, non-exclusive, non-transferable, non-sublicensable license to use the Product only for the purchaser’s internal research and development purposes. No right or license is granted, either expressly or by implication, estoppel, or otherwise, under any patent, trademark, copyright, or other intellectual property right of CellMosaic, except as expressly stated herein. Any commercial use of the Product is strictly prohibited without a separate written agreement from CellMosaic. Prohibited commercial uses include, without limitation: (a) the sale, lease, licensing, distribution, or other transfer of the Product or any materials derived from or produced using the Product; (b) the sale, lease, licensing, or other grant of rights to use the Product or any materials derived from or produced using the Product; and (c) the use of the Product to perform services for a fee or other consideration for third parties, including without limitation contract research, screening services, or diagnostic or therapeutic applications. For information regarding commercial licensing or collaboration, please contact us at info@cellmosaic.com.
